

Supplemental Approvals

Generic Name (Trade Name—Company)

January 31, 2011

Uses/Notes

Treatment of postherpetic neuralgia

Gabapentin

(*Gralise—Depomed*)

Once-daily formulation

This new [once-daily formulation of gabapentin](#) is designed to swell in the gastric fluid and gradually release the active drug. A dose of 1,800 mg/d resulted in a statistically significant reduction in average daily pain scores compared with placebo and was generally well tolerated. This new gabapentin formulation is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles. The tablets will be marketed in 300-mg and 600-mg dosage strengths and will be available later this year.

Source URL:

<http://aphanet.org/once-daily-formulation>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.